IN THE TREATMENT OF ACUTE CORONARY SYNDROME
DECISIONS TODAY CAN
IMPACT A LIFE
BRILINTA CAN HELP
BEYOND 30 DAYS, BEYOND THE HOSPITAL,
BETTER EFFICACY THAN CLOPIDOGREL
AT 30 DAYS, BRILINTA plus aspirin reduced the primary
composite end point of cardiovascular (CV) death,
myocardial infarction (MI),* or stroke by 12% RRR†
(ARR‡ 0.6%) vs clopidogrel plus aspirin.§1,2
AT 12 MONTHS, BRILINTA plus aspirin signi?cantly
reduced the primary composite end point by 16% RRR
(ARR 1.9%) vs clopidogrel plus aspirin. The difference
between treatments was driven by CV death and MI
with no difference in stroke.§1
IMPORTANT SAFETY INFORMATION ABOUT BRILINTA
WARNING: BLEEDING RISK
• BRILINTA, like other antiplatelet agents, can cause
signi?cant, sometimes fatal, bleeding
• Do not use BRILINTA in patients with active
pathological bleeding or a history of intracranial
hemorrhage
• Do not start BRILINTA in patients planned to undergo
urgent coronary artery bypass graft surgery (CABG).
When possible, discontinue BRILINTA at least 5 days
prior to any surgery
• Suspect bleeding in any patient who is hypotensive
and has recently undergone coronary angiography,
percutaneous coronary intervention (PCI), CABG,
or other surgical procedures in the setting of BRILINTA
• If possible, manage bleeding without discontinuing
BRILINTA. Stopping BRILINTA increases the risk
of subsequent cardiovascular events
WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
• Maintenance doses of aspirin above 100 mg
reduce the effectiveness of BRILINTA and should
be avoided. After any initial dose, use with aspirin
75 mg–100 mg per day
CONTRAINDICATIONS
BRILINTA is contraindicated in patients with:
• History of intracranial hemorrhage
• Active pathological bleeding such as peptic ulcer
or intracranial hemorrhage
• Severe hepatic impairment because of a probable
increase in exposure; it has not been studied in
these patients. Severe hepatic impairment
increases the risk of bleeding because of
reduced synthesis of coagulation proteins
• Hypersensitivity (e.g. angioedema) to ticagrelor
or any component of the product